Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.
Bavetsias, V., Large, J.M., Sun, C., Bouloc, N., Kosmopoulou, M., Matteucci, M., Wilsher, N.E., Martins, V., Reynisson, J., Atrash, B., Faisal, A., Urban, F., Valenti, M., de Haven Brandon, A., Box, G., Raynaud, F.I., Workman, P., Eccles, S.A., Bayliss, R., Blagg, J., Linardopoulos, S., McDonald, E.(2010) J Med Chem 53: 5213-5228
- PubMed: 20565112 
- DOI: 10.1021/jm100262j
- Primary Citation of Related Structures:  
2X6D, 2X6E - PubMed Abstract: 
Lead optimization studies using 7 as the starting point led to a new class of imidazo[4,5-b]pyridine-based inhibitors of Aurora kinases that possessed the 1-benzylpiperazinyl motif at the 7-position, and displayed favorable in vitro properties. Cocrystallization of Aurora-A with 40c (CCT137444) provided a clear understanding into the interactions of this novel class of inhibitors with the Aurora kinases ...